Bristol Myers Squibb (CELG-RI) Retained Earnings (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Retained Earnings of -$1.4 billion for Q1 2026, down 108.51% year-over-year from $16.1 billion in Q1 2025, and up 10.1% quarter-over-quarter from -$1.5 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Retained Earnings (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Retained Earnings data on file, last reported at -$1.4 billion in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$1.4 billion, down 108.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 108.51% YoY), and the FY2025 annual result was -$1.5 billion, down 23.1% from the prior year.
- Retained Earnings rose to -$1.4 billion in Q1 2026 per CELG-RI's latest filing, from -$1.5 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $25.5 billion in Q4 2022 and troughed at -$1.6 billion in Q2 2025.
- A 5-year average of $7.4 billion and a median of -$1.2 billion in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 1351.71% in 2024, then plunged 108.51% in 2026.
- A 5-year view of Retained Earnings shows it stood at $25.5 billion in 2022, then plunged by 106.06% to -$1.5 billion in 2023, then increased by 19.92% to -$1.2 billion in 2024, then dropped by 23.1% to -$1.5 billion in 2025, then climbed by 10.1% to -$1.4 billion in 2026.
- Business Quant data shows CELG-RI's Retained Earnings at -$1.4 billion in Q1 2026, -$1.5 billion in Q4 2025, and $17.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Bn |
| Dec 31, 2025 | -1.52 Bn |
| Sep 30, 2025 | 17.09 Bn |
| Jun 30, 2025 | -1.55 Bn |
| Mar 31, 2025 | 16.11 Bn |
| Dec 31, 2024 | -1.24 Bn |
| Sep 30, 2024 | 16.10 Bn |
| Jun 30, 2024 | -1.46 Bn |
| Mar 31, 2024 | 15.64 Bn |
| Dec 31, 2023 | -1.55 Bn |
| Sep 30, 2023 | -1.29 Bn |
| Jun 30, 2023 | -1.39 Bn |
| Mar 31, 2023 | -1.37 Bn |
| Dec 31, 2022 | 25.50 Bn |
| Sep 30, 2022 | 24.68 Bn |
| Jun 30, 2022 | 24.22 Bn |
| Mar 31, 2022 | -1.23 Bn |
| Dec 31, 2021 | 23.82 Bn |
| Sep 30, 2021 | 22.63 Bn |
| Jun 30, 2021 | 22.17 Bn |